Senna is the fruit (pod) or leaf of the plant Senna alexandrina. It is approved in the US as a laxative for short-term treatment of constipation.

Senna contains many chemicals called sennosides. Sennosides irritate the lining of the bowel, which causes a laxative effect.

Senna is an FDA-approved over-the-counter (OTC) laxative. It is used to treat constipation and also to clear the bowel before procedures such as colonoscopy. People also use senna for irritable bowel syndrome (IBS), hemorrhoids, weight loss, and many other conditions, but there is no good scientific evidence to support these uses.

Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, Ineffective, and Insufficient Evidence to Rate.

The effectiveness ratings for SENNA are as follows:

Likely effective for…

• Constipation. Senna is an FDA-approved nonprescription (OTC) drug for adults and children ages 2 years and older. It should be taken at bedtime and tends to work within 6-12 hours. It might cause stomach upset and diarrhea. Senna should not be used for more than 1 week without the supervision of a healthcare provider.

Possibly effective for…

• Emptying the colon before a colonoscopy. Taking senna by mouth might help empty the colon before a colonoscopy. Prior to a colonoscopy, your doctor will recommend a specific regimen to use in order to ensure that your colon is empty prior to the procedure.

There is interest in using senna for a number of other purposes, but there isn’t enough reliable information to say whether it might be helpful.

When taken by mouth: Senna is likely safe for most adults when used for up to 1 week. Senna is an FDA-approved nonprescription (OTC) medicine. It can cause some side effects including stomach discomfort, cramps, and diarrhea.

Senna is possibly unsafe when used for longer than 1 week or in doses above 34.4 mg sennosides twice daily. Long-term use can cause the bowels to stop functioning normally and might cause dependence on laxatives. Long-term use can also cause liver damage and other harmful effects.

Special precautions & warnings:

Pregnancy: Senna is possibly safe when taken by mouth during pregnancy for up to 1 week. It is possibly unsafe when taken by mouth for longer than 1 week or in high doses. This has been linked to serious side effects including laxative dependence and liver damage.

Breast-feeding: Senna is possibly safe when taken by mouth during breast-feeding for up to 1 week. Small amounts of senna cross into breast milk, but it doesn’t seem to be a problem for nursing babies. As long as senna is used in recommended amounts, it doesn’t cause changes in the babies’ stools.

Children: Senna is likely safe for children over age 2 when taken by mouth for up to 1 week. It is an FDA-approved nonprescription (OTC) medicine that can cause some side effects including stomach discomfort, cramps, and diarrhea. Senna is possibly unsafe when taken by mouth for longer than 1 week or in high doses. Children ages 2-5 shouldn’t take more than 8.6 mg sennosides twice daily. Children ages 6-11 shouldn’t take more than 17.2 mg sennosides twice daily. Children 12 years and older shouldn’t take more than 34.4 mg sennosides twice daily.

Gastrointestinal (GI) conditions: Senna should not be used by people with stomach pain, intestinal blockage, inflammatory bowel disease, diarrhea, appendicitis, stomach inflammation, or hemorrhoids.

Moderate

Be cautious with this combination.

Digoxin (Lanoxin)

Senna is a type of laxative called a stimulant laxative. Stimulant laxatives can decrease potassium levels in the body. Low potassium levels can increase the risk of side effects from digoxin.

Estrogens

Taking senna might decrease the effects of estrogen. Senna can reduce the amount of estrogen in the body and how much estrogen the body absorbs.

Warfarin (Coumadin)

Senna can work as a laxative. In some people, senna can cause diarrhea. Diarrhea can increase the effects of warfarin and increase the risk of bleeding. If you take warfarin, do not take excessive amounts of senna.

Water pills (Diuretic drugs)

Senna is a laxative. Some laxatives can cause diarrhea and decrease potassium levels. “Water pills” can also decrease potassium levels. Taking senna along with “water pills” might make potassium levels drop too low.

Horsetail

Using senna along with horsetail might cause potassium levels to drop too low.

Licorice

Using senna along with licorice might cause potassium levels to drop too low.

Stimulant laxative herbs

Senna is a type of laxative called a stimulant laxative. Stimulant laxatives can cause diarrhea and decrease potassium levels. Taking senna with other supplements with similar effects might cause more diarrhea and very low potassium levels. Examples of supplements with this effect include aloe, buckthorn, gossypol, and rhubarb.

There are no known interactions with foods.

Senna is most often used by adults in doses of 17.2 mg sennosides by mouth, once or twice daily. Recommended doses in children vary by age. Speak with a healthcare provider to find out what dose might be best for a specific condition.

Alexandrian Senna, Alexandrinische Senna, Casse, Cassia acutifolia, Cassia angustifolia, Cassia lanceolata, Cassia senna, Fan Xie Ye, Indian Senna, Khartoum Senna, Sen, Sena Alejandrina, Séné, Séné d’Alexandrie, Séné d’Egypte, Séne d’Inde, Séné de Tinnevelly, Senna alexandrina, Sennae Folium, Sennae Fructus, Sennosides, Tinnevelly Senna, True Senna.

To learn more about how this article was written, please see the Natural Medicines Comprehensive Database methodology.

1. Morishita D, Tomita T, Mori S, et al. Senna Versus Magnesium Oxide for the Treatment of Chronic Constipation: A Randomized, Placebo-Controlled Trial. Am J Gastroenterol 2021;116:152-161. View abstract.
2. Irazábal B, Sánchez de Vicente J, Galán C, et al. Anaphylaxis Due to Senna (Cassia angustifolia). J Investig Allergol Clin Immunol 2021;31:71-73. View abstract.
3. Haoudar A, Chekhlabi N, El Kettani C, Dini N. Acute Hepatitis and Pancytopenia in a Child With Chronic Abuse of Senna. Cureus 2021;13:e12436. View abstract.
4. Coskun Y, Yuksel I. Polyethylene glycol versus split high-dose senna for bowel preparation: A comparative prospective randomized study. J Gastroenterol Hepatol 2020;35:1923-1929. View abstract.
5. Cogley K, Echevarria A, Correa C, De la Torre-Mondragón L. Contact Burn with Blister Formation in Children Treated with Sennosides. Pediatr Dermatol 2017;34:e85-e88. View abstract.
6. Vilanova-Sanchez A, Gasior AC, Toocheck N, et al. Are Senna based laxatives safe when used as long term treatment for constipation in children? J Pediatr Surg 2018;53:722-7. View abstract.
7. Chen HB, Lian-Xiang P, Yue H, et al. Randomized controlled trial of 3 days fasting and oral senna, combined with mannitol and simethicone, before capsule endoscopy. Medicine (Baltimore) 2017;96:e8322. View abstract.
8. Senokot Package Labeling, Purdue Products, L.P. 2016
9. Poyrazoglu OK, Yalniz M. Two low-dose bowel-cleansing regimens: efficacy and safety of senna and sodium phosphorus solution for colonoscopy. Patient Prefer Adherence 2015;9:1325-31.View abstract.
10. Yenidogan E, Okan I, Kayaoglu HA, et al. Same-day colonoscopy preparation with Senna alkaloids and bisacodyl tablets: a pilot study. World J Gastroenterol 2014;20:15382-6.View abstract.
11. Feudtner C, Freedman J, Kang T, Womer JW, Dai D, Faerber J. Comparative effectiveness of senna to prevent problematic constipation in pediatric oncology patients receiving opioids: a multicenter study of clinically detailed administrative data. J Pain Symptom Manage 2014;48:272-80.View abstract.
12. National Toxicology Program. Toxicology study of senna (CAS No. 8013-11-4) in C57BL/6NTAC mice and toxicology and carcinogenesis study of senna in genetically modified C3B6.129F1/Tac-Trp53tm1Brd haploinsufficient mice (feed studies). Natl Toxicol Program Genet Modif Model Rep 2012;:1-114.View abstract.
13. Unal, S., Dogan, U. B., Ozturk, Z., and Cindoruk, M. A randomized prospective trial comparing 45 and 90-ml oral sodium phosphate with X-Prep in the preparation of patients for colonoscopy. Acta Gastroenterol.Belg. 1998;61:281-284. View abstract.
14. van Gorkom, B. A., Karrenbeld, A., Limburg, A. J., and Kleibeuker, J. H. The effect of sennosides on colonic mucosal histology and bowel preparation. Z.Gastroenterol. 1998;36:13-18. View abstract.
15. Lewis, S. J., Oakey, R. E., and Heaton, K. W. Intestinal absorption of oestrogen: the effect of altering transit-time. Eur.J Gastroenterol.Hepatol. 1998;10:33-39. View abstract.
16. Agra, Y., Sacristan, A., Gonzalez, M., Ferrari, M., Portugues, A., and Calvo, M. J. Efficacy of senna versus lactulose in terminal cancer patients treated with opioids. J Pain Symptom.Manage. 1998;15:1-7. View abstract.
17. Lewis, S. J., Heaton, K. W., Oakey, R. E., and McGarrigle, H. H. Lower serum oestrogen concentrations associated with faster intestinal transit. Br.J Cancer 1997;76:395-400. View abstract.
18. Sykes, N. P. A volunteer model for the comparison of laxatives in opioid-related constipation. J Pain Symptom.Manage. 1996;11:363-369. View abstract.
19. Maddi, V. I. Regulation of bowel function by a laxative/stool softener preparation in aged nursing home patients. J Am Geriatr.Soc. 1979;27:464-468. View abstract.
20. Corman, M. L. Management of postoperative constipation in anorectal surgery. Dis.Colon Rectum 1979;22:149-151. View abstract.
21. Fernandez, Seara J., Pascual, Rubin P., Pato Rodriguez, M. A., Pereira Jorge, J. A., Dominguez Alvarez, L. M., Landeiro, Aller E., Tesouro, Rodriguez, I, Gonzalez Simon, M. C., Mendez Veloso, M. C., and Pena, Perez L. [Comparative study of the efficacy and tolerance of 2 types of colon cleansing]. Rev.Esp.Enferm.Dig. 1995;87:785-791. View abstract.
22. de Witte, P. Metabolism and pharmacokinetics of anthranoids. Pharmacology 1993;47 Suppl 1:86-97. View abstract.
23. Kaspi, T., Royds, R. B., and Turner, P. Qualitative determination of senna in urine. Lancet 5-27-1978;1:1162. View abstract.
24. Kobashi, K., Nishimura, T., Kusaka, M., Hattori, M., and Namba, T. Metabolism of sennosides by human intestinal bacteria. Planta Med 1980;40:225-236. View abstract.
25. Malmquist, J., Ericsson, B., Hulten-Nosslin, M. B., Jeppsson, J. O., and Ljungberg, O. Finger clubbing and aspartylglucosamine excretion in a laxative-abusing patient. Postgrad.Med J 1980;56:862-864. View abstract.
26. Gould, S. R. and Williams, C. B. Castor oil or senna preparation before colonoscopy for inactive chronic ulcerative colitis. Gastrointest.Endosc. 1982;28:6-8. View abstract.
27. Brouwers, J. R., van Ouwerkerk, W. P., de Boer, S. M., and Thoman, L. A controlled trial of senna preparations and other laxatives used for bowel cleansing prior to radiological examination. Pharmacology 1980;20 Suppl 1:58-64. View abstract.
28. Pers, M. and Pers, B. A crossover comparative study with two bulk laxatives. J Int.Med Res 1983;11:51-53. View abstract.
29. Levine, D., Goode, A. W., and Wingate, D. L. Purgative abuse associated with reversible cachexia, hypogammaglobulinaemia, and finger clubbing. Lancet 4-25-1981;1:919-920. View abstract.
30. Greiner, A. C. and Warwick, W. E. The use of sennosides A and B in the treatment of constipation in a mental institution. Appl.Ther 1965;7:1096-1098. View abstract.
31. Glatzel, H. [Results of long-term therapy of 1059 babitually constipated patients using a standardized senna preparation]. Z.Allgemeinmed. 5-10-1972;48:654-656. View abstract.
32. Sanders, R. C. and Wright, F. W. Colonic preparation: a controlled trial of Dulcodos, Dulcolax and Senokot DX. Br.J Radiol. 1970;43:245-247. View abstract.
33. Slanger, A. Comparative study of a standardized senna liquid and castor oil in preparing patients for radiographic examination of the colon. Dis.Colon Rectum 1979;22:356-359. View abstract.
34. Connolly, P., Hughes, I. W., and Ryan, G. Comparison of “Duphalac” and “irritant” laxatives during and after treatment of chronic constipation: a preliminary study. Curr Med Res Opin. 1974;2:620-625. View abstract.
35. Greenhalf, J. O. and Leonard, H. S. Laxatives in the treatment of constipation in pregnant and breast-feeding mothers. Practitioner 1973;210:259-263. View abstract.
36. Pockros, P. J. and Foroozan, P. Golytely lavage versus a standard colonoscopy preparation. Effect on normal colonic mucosal histology. Gastroenterology 1985;88:545-548. View abstract.
37. van der Jagt, E. J., Thijn, C. J., and Taverne, P. P. Colon cleansing prior to roentgenologic examination. A double blind comparative study. J Belge Radiol. 1986;69:167-170. View abstract.
38. Lemli, J. Metabolism of sennosides–an overview. Pharmacology 1988;36 Suppl 1:126-128. View abstract.
39. Heldwein, W., Sommerlatte, T., Hasford, J., Lehnert, P., Littig, G., and Muller-Lissner, S. Evaluation of the usefulness of dimethicone and/or senna extract in improving the visualization of abdominal organs. J Clin.Ultrasound 1987;15:455-458. View abstract.
40. Kinnunen, O. and Salokannel, J. The carry-over effect on the bowel habit in elderly long-term patients of long-term bulk-forming products containing stimulant laxative. Acta Med Scand. 1987;222:477-479. View abstract.
41. Bossi, S., Arsenio, L., Bodria, P., Magnati, G., Trovato, R., and Strata, A. [Clinical study of a new preparation from plantago seeds and senna pods]. Acta Biomed.Ateneo.Parmense. 1986;57(5-6):179-186. View abstract.
42. Mishalany, H. Seven years’ experience with idiopathic unremitting chronic constipation. J Pediatr.Surg. 1989;24:360-362. View abstract.
43. Labenz, J., Hopmann, G., Leverkus, F., and Borsch, G. [Bowel cleansing prior to colonoscopy. A prospective, randomized, blind comparative study]. Med Klin.(Munich) 10-15-1990;85:581-585. View abstract.
44. Lazarus, H., Fitzmartin, R. D., and Goldenheim, P. D. A multi-investigator clinical evaluation of oral controlled-release morphine (MS Contin tablets) administered to cancer patients. Hosp.J 1990;6:1-15. View abstract.
45. Ziegenhagen, D. J., Zehnter, E., Tacke, W., and Kruis, W. Addition of senna improves colonoscopy preparation with lavage: a prospective randomized trial. Gastrointest.Endosc. 1991;37:547-549. View abstract.
46. Soyuncu, S., Cete, Y., and Nokay, A. E. Portal vein thrombosis related to Cassia angustifolia. Clin.Toxicol.(Phila) 2008;46:774-777. View abstract.
47. Wildgrube, H. J. and Lauer, H. [Combination intestinal lavage: a conservative procedure for colonoscopy]. Bildgebung 1991;58:63-66. View abstract.
48. McLaughlin, A. F. Anorexia nervosa and senna misuse: nephrocalcinosis, digital clubbing and hypertrophic osteoarthropathy. Med J Aust. 9-15-2008;189:348. View abstract.
49. Lim, A. K., Hooke, D. H., and Kerr, P. G. Anorexia nervosa and senna misuse: nephrocalcinosis, digital clubbing and hypertrophic osteoarthropathy. Med J Aust. 1-21-2008;188:121-122. View abstract.
50. Bailey, S. R., Tyrrell, P. N., and Hale, M. A trial to assess the effectiveness of bowel preparation prior to intravenous urography. Clin.Radiol. 1991;44:335-337. View abstract.
51. De, Salvo L., Borgonovo, G., Ansaldo, G. L., Varaldo, E., Floris, F., Assalino